MedTrace Logo

Stromal Vascular Fraction (SVF) for Treatment of Enterocutaneous Fistula (HULPUTC)

NCT01584713 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2012-04-25

No results posted yet for this study

Summary

The purpose of this study is to determine safety of Stromal Vascular Fraction (SVF) for the treatment of enterocutaneous fistula.

Conditions

  • Enterocutaneous Fistula

Interventions

DRUG

Adipose-derived stem cells without expanded

Administration will be intralesional injection of cells suspension. They will be placed into fistula walls

Sponsors & Collaborators

  • Instituto de Investigación Hospital Universitario La Paz

    lead OTHER

Principal Investigators

  • Mariano Garcia-Arranz, Doctor · Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2012-07-31
Completion
2013-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01584713 on ClinicalTrials.gov